Gastroenterological conditions, including irritable bowel syndrome (IBS), Crohn’s disease, ulcerative colitis, and acid reflux, affect millions of people worldwide. These conditions often cause symptoms such as abdominal pain, bloating, inflammation, diarrhea, nausea, and poor appetite, significantly impacting daily life and overall well-being. While traditional treatments, such as anti-inflammatory drugs and dietary modifications, can be effective, they are not always sufficient and may come with side effects.
Medical cannabis, containing compounds like THC (Tetrahydrocannabinol) and CBD (Cannabidiol), has emerged as a promising therapy for managing gastrointestinal (GI) disorders. Research indicates that cannabis can help regulate inflammation, reduce pain, and improve quality of life for those with chronic GI conditions.
THC binds to the brain and gut’s endocannabinoid receptors, reducing pain, calming muscle spasms, and promoting relaxation. It also helps alleviate nausea and stimulates appetite, making it beneficial for GI conditions associated with weight loss or malnutrition.
CBD is non-psychoactive and works as an anti-inflammatory and immune-modulating agent, helping to reduce intestinal inflammation and ease symptoms of chronic GI conditions.
THC and CBD reduce abdominal pain and cramping by interacting with the body’s endocannabinoid system to calm overactive nerve signals.
THC can stimulate appetite, which is often reduced in GI conditions, helping patients maintain a healthy weight.
CBD’s anti-inflammatory properties help manage conditions like Crohn’s disease and ulcerative colitis, reducing flare-ups and promoting remission.
Cannabis is effective in managing nausea caused by GI disorders or side effects of treatments like chemotherapy.
Cannabis (THC) for IBS can help normalise bowel movements, reducing symptoms like diarrhea or constipation in IBS and other functional GI disorders.
A 2021 study in Gastroenterology & Hepatology found that 65% of patients with Crohn’s disease using
Medical
cannabis experienced significant symptom relief.
Up to 91% of IBS patients reported improved symptom control with cannabis, according to a 2020 survey published in Digestive Diseases and Sciences.
A 2019 study found that medical cannabis reduced the severity of abdominal pain by 30-50% in patients with chronic GI conditions.
Cannabis has been shown to improve quality of life scores in 75% of patients with ulcerative colitis, according to a 2020 study in PLOS ONE.
While medical cannabis offers considerable benefits for managing gastroenterological conditions, proper dosage and cannabinoid composition are crucial to avoid side effects, such as altered gut motility from excessive THC. Medical supervision is essential to develop a treatment plan tailored to individual needs.
Medical cannabis may help reduce abdominal pain, inflammation, and discomfort related to chronic GI conditions. By improving digestive health and easing symptoms, it can offer day-to-day relief when traditional treatments fall short.
Every patient responds differently, working with a healthcare provider helps ensure the safest, most effective plan for your needs.
